The risk groups for preventive medication against RSV have been confirmed
In Finland, nirsevimab will be offered to all children born during the 2024-2025 winter RSV epidemic and to those under three months of age when the epidemic starts.
Distribution of TYKS Foundation research grants to a new level in 2024
In 2024, the TYKS Foundation will allocate significantly more money to medical and health sciences research than before. This is enabled by significant donations received by the Foundation.
